FORM PTO-1390 (REV . 120-2004)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US)** **CONCERNING A FILING UNDER 35 U.S.C. 371**		21415-0015US
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/534,130

| INTERNATIONAL APPLICATION NO. PCT/AU03/01487	INTERNATIONAL FILING DATE 10 November 2003 (10.11.2003)	PRIORITY DATE CLAIMED 08 November 2002 (08.11.2002)

TITLE OF INVENTION

A METHOD FOR OPTIMISING GENE EXPRESSION USING SYNONYMOUS CODON OPTIMISATION

APPLICANT(S) FOR DO/EO/US

Ian Hector FRAZER

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.

2. ☒ This is a **SECOND or SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.

3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f). The submission must include items (5), (6), (9) and (21) indicated below.

4. ☐ The US has been elected (Article 31).

5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))

   a. ☐ is attached hereto (required only if not communicated by the International Bureau).

   b. ☐ has been communicated by the International Bureau.

   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).

6. ☐ A English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).

   a. ☐ is attached hereto.

   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).

7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))

   a. ☐ are attached hereto (required only if not communicated by the International Bureau).

   b. ☐ had been communicated by the International Bureau.

   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.

   d. ☐ have not been made and will not be made.

8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).

9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included

13. ☐ A preliminary amendment.

14. ☐ An Application Data Sheet under 37 CFR 1.76.

15. ☐ A substitute specification.

16. ☐ A power of attorney and/or address letter.

17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 132 and 37 CFR 1.821-1825

18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4)

19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

20. ☒ Other items or information: copy of Notice (dated 3/10/06)

21. The following fees are submitted:

CALCULATIONS PTO USE ONLY

☐ a) Basic national fee...$300.00

☐ b) Examination fee $200.00

☐ c) Search fee..$500.00

TOTAL OF ABOVE CALCULATIONS = $

☐ Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is $250 for each additional 50 sheets of paper or fraction thereof.

$

TOTAL SHEETS	EXTRA SHEETS	NUMBER EXTRA (of each additional 50 or fraction thereof rounded up to a whole number)	RATE
-100 =	/50 =		x $250.00

Surcharge of $130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =		x $50.00	$	
Independent claims	- 3 =		x $200.00	$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ $360.00	$	

TOTAL OF ABOVE CALCULATIONS = $

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.

$

SUBTOTAL = $

Processing fee of $130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +

TOTAL NATIONAL FEE = $

Fee for recording the enclose assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property +

$

TOTAL FEES ENCLOSED = $ ($0 fees due)

Amount to be refunded:	$
Amount to be charged:	$

a. ☐ A check in the amount of $ _____ to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.

A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment

To Deposit Account No. **08-1641** A duplicate coy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING: Information on this form may become public. Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

HELLER EHRMAN LLP
1717 Rhode Island Avenue, N.W.
Washington, DC 20036
Customer No. : 26633

SIGNATURE _Patricia D. Granados_ 3/28/06

NAME   Date

Patricia D. Granados

REGISTRATION NUMBER

33,683

R**d PCT/PTO 28 MAR 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/534,130	Ian Hector Frazer	21415-0015

26633
HELLER EHRMAN WHITE & MCAULIFFE LLP
1717 RHODE ISLAND AVE, NW
WASHINGTON, DC 20036-3001

INTERNATIONAL APPLICATION NO.	
PCT/AU03/01487	
I.A. FILING DATE	PRIORITY DATE
11/10/2003	11/08/2002

CONFIRMATION NO. 8451
371 FORMALITIES LETTER

OC000000018255745

Date Mailed: 03/10/2006

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Priority Document
- Copy of the International Application filed on 05/06/2005
- Copy of the International Search Report filed on 05/06/2005
- Copy of IPE Report filed on 05/06/2005
- Copy of Annexes to the IPER filed on 05/06/2005
- Preliminary Amendments filed on 12/30/2005
- Information Disclosure Statements filed on 12/30/2005
- Biochemical Sequence Diskette filed on 12/30/2005
- Oath or Declaration filed on 12/30/2005
- Biochemical Sequence Listing filed on 12/30/2005
- Copy of references cited in ISR filed on 12/30/2005
- U.S. Basic National Fees filed on 05/06/2005
- Priority Documents filed on 05/06/2005
- Power of Attorney filed on 12/30/2005
- Specification filed on 05/06/2005
- Claims filed on 05/06/2005
- Abstracts filed on 05/06/2005
- Paper nucleotide sequence listings filed on 05/06/2005

Applicant's response filed 12/30/2005 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 09/30/2005 have not been completed.

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR

1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/534,130	PCT/AU03/01487	21415-0015

FORM PCT/DO/EO/916 (371 Formalities Notice)

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: _____ 10/534,130 _____

Source: _____ PCT _____

Date Processed by STIC: _____ 01/31/2006 _____

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**
FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO **REDUCE** ERRORED SEQUENCE LISTINGS, **PLEASE** USE THE **CHECKER VERSION 4.2.2 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
> **http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm**

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm> , **EFS Submission User Manual** - ePAVE)
2. **U.S. Postal Service:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. **Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):**
   U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: _10/534,130_

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1____Wrapped Nucleics / Wrapped Aminos — The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor **after** creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2____Invalid Line Length — The rules require that a line **not exceed** 72 characters in length. This includes white spaces.

3____Misaligned Amino Numbering — The numbering under each 5th amino acid is misaligned. Do **not** use tab codes between numbers; use **space characters**, instead.

4____Non-ASCII — The submitted file was **not** saved in ASCII(DOS) text, as **required** by the Sequence Rules. **Please ensure your subsequent submission is saved in ASCII text.**

5____Variable Length — Sequence(s)____contain n's or Xaa's representing more than one residue. **Per Sequence Rules, each n or Xaa can only represent a single residue.** Please present the **maximum** number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6____PatentIn 2.0 "bug" — A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.**

7____Skipped Sequences (OLD RULES) — Sequence(s) ____ missing. If intentional, please insert the following lines for **each** skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i)   SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to **include** the skipped sequences.

8____Skipped Sequences (NEW RULES) — Sequence(s) _____ missing. If **intentional**, please insert the following lines for **each** skipped sequence.
<210> sequence id number
<400> sequence id number
000

9____Use of n's or Xaa's (NEW RULES) — Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of **n** or **Xaa**, and which residue n or Xaa represents.

10____Invalid <213> Response — Per 1.823 of Sequence Rules, the only **valid** <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is **required** when <213> response is Unknown or is Artificial Sequence

11____Use of <220> — Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of Sequence Rules)

12____PatentIn 2.0 "bug" — Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13____Misuse of n/Xaa — "n" can **only** represent a single <u>nucleotide</u>; "Xaa" can **only** represent a single <u>amino acid</u>

PCT

```
 3 <110> APPLICANT: Ian Hector Frazer
 5 <120> TITLE OF INVENTION: A method for optimising gene expression using
 6       synonymous codon optimisation
 8 <130> FILE REFERENCE: 21415-0015US
C--> 10 <140> CURRENT APPLICATION NUMBER: US/10/534,130
11 <141> CURRENT FILING DATE: 2005-05-06
13 <150> PRIOR APPLICATION NUMBER: PCT/AU2003/001487
14 <151> PRIOR FILING DATE: 2003-11-10
16 <150> PRIOR APPLICATION NUMBER: USSN 60/425,163
17 <151> PRIOR FILING DATE: 2002-11-08
19 <160> NUMBER OF SEQ ID NOS: 126·
21 <170> SOFTWARE: PatentIn version 3.2
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 714
25 <212> TYPE: DNA
26 <213> ORGANISM: Artificial Sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: Humanised GFP
32 <220> FEATURE:
33 <221> NAME/KEY: CDS
34 <222> LOCATION: (1)..(711)
36 <400> SEQUENCE: 1
37 agc aag ggc gag gaa ctg ttc act ggc gtg gtc cca att ctc gtg gaa      48
38 Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu
39 1               5                   10                  15
41 ctg gat ggc gat gtg aat ggg cac aaa ttt tct gtc agc gga gag ggt      96
42 Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly
43             20                  25                  30
45 gaa ggt gat gcc aca tac gga aag ctc acc ctg aaa ttc atc tgc acc     144
46 Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr
47         35                  40                  45
49 act gga aag ctc cct gtg cca tgg cca aca ctg gtc act acc ttc tct     192
50 Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe Ser
51     50                  55                  60
53 tat ggc gtg cag tgc ttt tcc aga tac cca gac cat atg aag cag cat     240
54 Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His
55 65                  70                  75                  80
57 gac ttt ttc aag agc gcc atg ccc gag ggc tat gtg cag gag aga acc     288
58 Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr
59             85                  90                  95
61 atc ttt ttc aaa gat gac ggg aac tac aag acc cgc gct gaa gtc aag     336
62 Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys
63             100                 105                 110
```

Does Not Comply
Corrected Diskette Needed
(pg-3,4,5)

```
65 ttc gaa ggt gac acc ctg gtg aat aga atc gag ctg aag ggc att gac      384
66 Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp
67         115                 120                 125
69 ttt aag gag gat gga aac att ctc ggc cac aag ctg gaa tac aac tat      432
70 Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr
71         130                 135                 140
73 aac tcc cac aat gtg tac atc atg gcc gac aag caa aag aat ggc atc      480
74 Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile
75 145               ,   150                 155                 160
77 aag gtc aac ttc aag atc aga cac aac att gag gat gga tcc gtg cag      528
78 Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln
79                 165                 170                 175
81 ctg gcc gac cat tat caa cag aac act cca atc ggc gac ggc cct gtg      576
82 Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val
83         180                 185                 190
85 ctc ctc cca gac aac cat tac ctg tcc acc cag tct gcc ctg tct aaa      624
86 Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys
87         195                 200                 205
89 gat ccc aac gaa aag aga gac cac atg gtc ctg ctg gag ttt gtg acc      672
90 Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr
91         210                 215                 220
93 gct gct ggg atc aca cat ggc atg gac gag ctg tac aag tga            714
94 Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
95 225                 230                 235
98 <210> SEQ ID NO: 2
99 <211> LENGTH: 237
100 <212> TYPE: PRT
101 <213> ORGANISM: Artificial Sequence
103 <220> FEATURE:
104 <223> OTHER INFORMATION: Humanised GFP
106 <400> SEQUENCE: 2
108 Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu
109 1               5                   10                  15
112 Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly
113             20                  25                  30
116 Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr
117             35                  40                  45
120 Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe Ser
121     50                  55                  60
124 Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His
125 65                  70                  75                  80
128 Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr
129             85                  90                  95
132 Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys
133             100                 105                 110
136 Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp
137             115                 120                 125
140 Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr
141         130                 135                 140
```

RAW SEQUENCE LISTING   DATE: 01/31/2006
PATENT APPLICATION: US/10/534,130   TIME: 16:12:34

Input Set : A:\PTO.TS.31.txt
Output Set: N:\CRF4\01312006\J534130.raw

```
144 Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile
145 145                 150                 155                 160
148 Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln
149                 165                 170                 175
152 Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val
153                 180                 185                 190
156 Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys
157         195                 200                 205
160 Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr
161     210                 215                 220
164 Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
165 225                 230                 235
168 <210> SEQ ID NO: 3
169 <211> LENGTH: 18
170 <212> TYPE: DNA
171 <213> ORGANISM: Artificial Sequence
173 <220> FEATURE:
174 <223> OTHER INFORMATION: Ala(GCA)x6
177 <220> FEATURE:
178 <221> NAME/KEY: CDS
179 <222> LOCATION: (1)..(18)
181 <400> SEQUENCE: 3
182 gca gca gca gca gca gca                                      18
183 Ala Ala Ala Ala Ala Ala
184 1               5
187 <210> SEQ ID NO: 4
188 <211> LENGTH: 6
189 <212> TYPE: PRT
190 <213> ORGANISM: Artificial Sequence
192 <220> FEATURE:
193 <223> OTHER INFORMATION: Ala(GCA)x6
195 <400> SEQUENCE: 4
197 Ala Ala Ala Ala Ala Ala
198 1               5
201 <210> SEQ ID NO: 5
202 <211> LENGTH: 18
203 <212> TYPE: DNA
204 <213> ORGANISM: Artificial Sequence
206 <220> FEATURE:
207 <223> OTHER INFORMATION: Ala(GCG)x6
210 <220> FEATURE:
211 <221> NAME/KEY: CDS
212 <222> LOCATION: (1)..(18)
214 <400> SEQUENCE: 5
215 gcg gcg gcg gcg gcg gcg                                      18
216 Ala Ala Ala Ala Ala Ala
217 1               5
220 <210> SEQ ID NO: 6
221 <211> LENGTH: 6
```

[Handwritten annotations:] → Invalid Response. Pls Explain the Source of genetic Material. See Item #11 on Error Summary Sheet.

→ Same error

RAW SEQUENCE LISTING
PATENT APPLICATION: **US/10/534,130**

DATE: 01/31/2006
TIME: 16:12:34

Input Set : **A:\PTO.TS.31.txt**
Output Set: **N:\CRF4\01312006\J534130.raw**

```
222 <212> TYPE: PRT
223 <213> ORGANISM: Artificial Sequence
225 <220> FEATURE:
226 <223> OTHER INFORMATION: Ala(GCG)x6
228 <400> SEQUENCE: 6
230 Ala Ala Ala Ala Ala Ala
231 1               5
234 <210> SEQ ID NO: 7
235 <211> LENGTH: 18
236 <212> TYPE: DNA
237 <213> ORGANISM: Artificial Sequence
239 <220> FEATURE:
240 <223> OTHER INFORMATION: Ala(GCT)x6
243 <220> FEATURE:
244 <221> NAME/KEY: CDS
245 <222> LOCATION: (1)..(18)
247 <400> SEQUENCE: 7
248 gct gct gct gct gct gct                                        18
249 Ala Ala Ala Ala Ala Ala
250 1               5
253 <210> SEQ ID NO: 8
254 <211> LENGTH: 6
255 <212> TYPE: PRT
256 <213> ORGANISM: Artificial Sequence
258 <220> FEATURE:
259 <223> OTHER INFORMATION: Ala(GCT)x6
261 <400> SEQUENCE: 8
263 Ala Ala Ala Ala Ala Ala
264 1               5
267 <210> SEQ ID NO: 9
268 <211> LENGTH: 18
269 <212> TYPE: DNA
270 <213> ORGANISM: Artificial Sequence
272 <220> FEATURE:
273 <223> OTHER INFORMATION: Ala(GCC)x6
276 <220> FEATURE:
277 <221> NAME/KEY: CDS
278 <222> LOCATION: (1)..(18)
280 <400> SEQUENCE: 9
281 gcc gcc gcc gcc gcc gcc                                        18
282 Ala Ala Ala Ala Ala Ala
283 1               5
286 <210> SEQ ID NO: 10
287 <211> LENGTH: 6
288 <212> TYPE: PRT
289 <213> ORGANISM: Artificial Sequence
291 <220> FEATURE:
292 <223> OTHER INFORMATION: Ala(GCC)x6
294 <400> SEQUENCE: 10
```

Same Error

```
296 Ala Ala Ala Ala Ala Ala
297 1                   5
300 <210> SEQ ID NO: 11
301 <211> LENGTH: 18
302 <212> TYPE: DNA
303 <213> ORGANISM: Artificial Sequence
305 <220> FEATURE:
306 <223> OTHER INFORMATION: Arg(AGA)x6
309 <220> FEATURE:
310 <221> NAME/KEY: CDS
311 <222> LOCATION: (1)..(18)
313 <400> SEQUENCE: 11
314 aga aga aga aga aga aga                                    18
315 Arg Arg Arg Arg Arg Arg
316 1                   5
319 <210> SEQ ID NO: 12
320 <211> LENGTH: 6
321 <212> TYPE: PRT
322 <213> ORGANISM: Artificial Sequence
324 <220> FEATURE:
325 <223> OTHER INFORMATION: Arg(AGA)x6
327 <400> SEQUENCE: 12
329 Arg Arg Arg Arg Arg Arg
330 1                   5
333 <210> SEQ ID NO: 13
334 <211> LENGTH: 18
335 <212> TYPE: DNA
336 <213> ORGANISM: Artificial Sequence
338 <220> FEATURE:
339 <223> OTHER INFORMATION: Arg(CGA)x6
342 <220> FEATURE:
343 <221> NAME/KEY: CDS
344 <222> LOCATION: (1)..(18)
346 <400> SEQUENCE: 13
347 cga cga cga cga cga cga                                    18
348 Arg Arg Arg Arg Arg Arg
349 1                   5
352 <210> SEQ ID NO: 14
353 <211> LENGTH: 6
354 <212> TYPE: PRT
355 <213> ORGANISM: Artificial Sequence
357 <220> FEATURE:
358 <223> OTHER INFORMATION: Arg(CGA)x6
360 <400> SEQUENCE: 14
362 Arg Arg Arg Arg Arg Arg
363 1                   5
366 <210> SEQ ID NO: 15
367 <211> LENGTH: 18
368 <212> TYPE: DNA
```

Same Error

VERIFICATION SUMMARY
PATENT APPLICATION: **US/10/534,130**

DATE: 01/31/2006
TIME: 16:12:35

Input Set : **A:\PTO.TS.31.txt**
Output Set: **N:\CRF4\01312006\J534130.raw**

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number